Investigating biomarkers for diagnosing and tracking frontotemporal lobar degeneration.
Official title: Pathology-guided biofluid biomarker strategies for classification and progression of frontotemporal lobar degeneration (FTLD)
Funded at University of Pennsylvania · NIH-10885535 · Data updated 2026-11-12
This study is looking for ways to better understand and track frontotemporal lobar degeneration (FTLD) by finding helpful markers in body fluids, which could lead to better treatments and improve how we monitor the disease for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 30, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $805,790 |
| NIH project number | 1R01AG087258-01 |
| Project ID | NIH-10885535 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with frontotemporal lobar degeneration or those with a genetic predisposition to the disease.
✕Less likely to help
Patients with other forms of dementia or neurodegenerative diseases unrelated to FTLD may not benefit from this research.
What this research studies
This research focuses on frontotemporal lobar degeneration (FTLD), a group of neurodegenerative diseases that currently lack effective treatments. The study aims to identify and develop biomarkers from biofluids like cerebrospinal fluid and plasma to better classify and monitor the progression of FTLD. By analyzing a unique cohort of patients with confirmed FTLD, the researchers will create algorithms that can help in screening and prognosis. This approach seeks to improve the understanding of FTLD and facilitate more effective clinical trials.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic tools and monitoring strategies for patients with frontotemporal lobar degeneration.
How similar studies have gone: Previous research has shown promise in using biomarkers for other neurodegenerative diseases, suggesting potential success for this novel approach in FTLD.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Cousins, Katheryn Alexandra Quilico — University of Pennsylvania
- Study coordinator: Cousins, Katheryn Alexandra Quilico
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.